Management and outcomes of intraductal papillary mucinous neoplasms

被引:13
|
作者
Hipp, J.
Mohamed, S.
Pott, J.
Sick, O.
Makowiec, E.
Hopt, U. T.
Fichtner-Feigl, S.
Wittel, U. A.
机构
[1] Univ Freiburg, Dept Gen & Visceral Surg, Med Ctr, Freiburg, Germany
[2] Univ Freiburg, Dept Gen & Visceral Surg, Fac Med, Freiburg, Germany
来源
BJS OPEN | 2019年 / 3卷 / 04期
关键词
INTERNATIONAL STUDY-GROUP; PANCREATIC SURGERY; RISK; MORTALITY; IPMN; PANCREATICODUODENECTOMY; INSUFFICIENCY; DEFINITION; MALIGNANCY; GUIDELINES;
D O I
10.1002/bjs5.50156
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background: This study evaluated the outcome and survival of patients with radiologically suspected intraductal papillary mucinous neoplasms (IPMNs). Methods: IPMN management was reviewed according to Fukuoka risk factors and IPMN localization, differentiating main-duct (MD), mixed-type (MT) and branch-duct (BD) IPMNs. Perioperative results were compared with those of patients undergoing resection of pancreatic ductal adenocarcinoma (PDAC) over the same interval (2010-2014). Overall (OS) and disease-specific (DSS) survival rates were calculated and subgroups compared. Results: Of 142 patients with IPMNs, 26 hadMD-IPMN, eight hadMT-IPMN and 108 had BD-IPMN. Some 74 per cent of patients with MD-and MT-IPMN were managed by primary resection, whereas this was used in only 27.8 per cent of those with BD-IPMN. The risk of secondary resection and malignant transformation for BD-IPMNs smaller than 20mm was 8 and 2 per cent respectively during follow-up. Pancreatic head resection of IPMNs was associated with an increased risk of postoperative pancreatic fistula grade B/C compared with resection of PDAC (12 of 33 (36 per cent) versus 41 of 221 (18.6 per cent) respectively; P = 0.010), and greater morbidity and mortality (Clavien-Dindo grade III: 15 of 33 (45 per cent) versus 56 of 221 (25.3 per cent) respectively; grade IV: 1 (3 per cent) versus 7 (3.2 per cent); grade V:2 (6 per cent) versus 2 (0.9 per cent); P = 0.008). Five-year OS and DSS rates in patients with MD-IPMN were worse than those forMT-and BD-IPMN (OS: 44, 86 and 97.4 per cent respectively, P < 0.001; DSS: 60, 100 and 98.6 per cent; P < 0.001). Patients with invasive IPMN had worse OS and DSS rates than those with non-invasive dysplasia (OS: IPMN-carcinoma (10 patients) 33 per cent, high-grade dysplasia 100 per cent, intermediate-grade dysplasia 63 per cent, low grade-dysplasia 100 per cent, P < 0.001; DSS: IPMN-carcinoma 43 per cent, all grades of dysplasia 100 per cent, P < 0.001). Patients with high-risk stigmata had poorer survival than those without risk factors (OS: high-risk stigmata (35 patients) 55 per cent, worrisome features (31) 95 per cent, no risk factors (76) 100 per cent, P < 0.001; DSS: 71, 100 and 100 per cent respectively, P < 0.001). Conclusion: The risk of malignant transformation was very low for BD-IPMNs, but the development of high-risk stigmata was associated with disease-specific mortality. Patients with IPMN had greater morbidity after resection than those having resection of PDAC.
引用
收藏
页码:490 / 499
页数:10
相关论文
共 50 条
  • [1] Management of intraductal papillary mucinous neoplasms
    Crippa S.
    Castillo C.F.
    Current Gastroenterology Reports, 2008, 10 (2) : 136 - 143
  • [2] Management of intraductal papillary mucinous neoplasms of the pancreas
    Perez-Johnston, R.
    Lin J, D.
    Carlos, C. Fernandez-Del Castillo
    Sahani, D.
    MINERVA CHIRURGICA, 2009, 64 (05) : 477 - 487
  • [3] The management of intraductal papillary mucinous neoplasms of the pancreas
    Pollini, Tommaso
    Andrianello, Stefano
    Caravati, Andrea
    Perri, Giampaolo
    Malleo, Giuseppe
    Paiella, Salvatore
    Marchegiani, Giovanni
    Salvia, Roberto
    MINERVA CHIRURGICA, 2019, 74 (05) : 414 - 421
  • [4] The Management of Intraductal Papillary Mucinous Neoplasms of the Pancreas
    Allen, Peter J.
    SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA, 2010, 19 (02) : 297 - +
  • [5] Outcomes of Surgery for Intraductal Papillary Mucinous Neoplasms of the Pancreas
    Yasuhiro Fujino
    Yasuyuki Suzuki
    Takuro Yoshikawa
    Tetsuo Ajiki
    Takashi Ueda
    Ippei Matsumoto
    Yoshikazu Kuroda
    World Journal of Surgery, 2006, 30 : 1909 - 1914
  • [6] Outcomes of surgery for intraductal papillary mucinous neoplasms of the pancreas
    Fujino, Yasuhiro
    Suzuki, Yasuyuki
    Yoshikawa, Takuro
    Ajiki, Tetsuo
    Ueda, Takashi
    Matsumoto, Ippei
    Kuroda, Yoshikazu
    WORLD JOURNAL OF SURGERY, 2006, 30 (10) : 1909 - 1915
  • [7] Intraductal papillary mucinous neoplasms
    Sahora, Klaus
    Castillo, Carlos Fernandez-del
    CURRENT OPINION IN GASTROENTEROLOGY, 2015, 31 (05) : 424 - 429
  • [8] Intraductal Papillary Mucinous Neoplasms
    Goh, Brian K. P.
    Srinivasan, Nandhini
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2017, 225 (05) : 682 - 682
  • [9] Review of the diagnosis and management of intraductal papillary mucinous neoplasms
    Crippa, Stefano
    Arcidiacono, Paolo G.
    De Cobelli, Francesco
    Falconi, Massimo
    UNITED EUROPEAN GASTROENTEROLOGY JOURNAL, 2020, 8 (03) : 249 - 255
  • [10] Intraductal papillary mucinous neoplasms of the pancreas: diagnosis and management
    Liu Dongbin
    Li Fei
    Josefin, Bjoerk Werner
    Roland, Andersson
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2010, 22 (09) : 1029 - 1038